Clinical Decision Support
Comprehensive Next-Generation Sequencing (NGS) Genetic Risk Assessment For Pancreatitis and CFTR Related Disorders
& Add-on Panel ArielDx® Lipids
Targeted gene panel for early assessment of risk related to susceptibility to pancreatitis and related conditions
Most patients with a complex, chronic disorder don’t have a single cause for their disease. In fact, there are over 50 possible contributing factors related to pancreatitis that may combine to increase risk of future progression . Each patient has a unique combination of genetic and accumulated environmental risk factors that should be evaluated before reaching chronic stage, an irreversible and expensive condition to manage.
Ariel recognizes the challenges of caring for patients with complex chronic disease. To support your management of these patients, Ariel has developed a comprehensive approach to genetic testing that goes beyond Mendelian disorders. Our integrated genetic panel and curated clinical summary is designed specifically for providers to identify and diagnose the underlying causes of symptoms to support clinical management.
ArielDx® PancreatitisArielDx® Pancreatitis is a comprehensive next-generation sequencing panel of genes related to susceptibility to pancreatitis and related complications. ArielDx Pancreatitis tests for predisposition to both Mendelian (monogenic) and complex (multifactorial) forms of disease. A minority of pancreatitis patients have a monogenic cause of disease. Therefore, testing for predisposing risk variants in addition to monogenic disease variants assures a complete picture of known genetic predisposition. ArielDx Pancreatitis may be appropriate for anyone who has had unexplained attacks of acute pancreatitis, especially if they are under the age of 35, exhibit symptoms of pancreatic disease, such as abdominal pain after eating, chronic diarrhea, abnormal findings on a CT or MRI, or have an abnormal laboratory test linked to the pancreas.
Genes Included in Panel
CASR, CEL, CFTR, CLDN2, CPA1, CTRC, GGT1, PRSS1-2, PRSS3, SBDS, SLC26A9, SPINK1 and UBR1.
ArielDx® LipidsArielDx® Lipids is a next-generation sequencing panel for genes associated with abnormal lipid metabolism. Abnormal lipid metabolism can increase an individual’s risk for developing cardiovascular disease, fatty liver disease, and pancreatitis. It is an established cause of pancreatitis, accounting for up to 10% of acute pancreatitis cases . Variants in several genes can cause hereditary disorders of lipid metabolism or increase an individual’s risk for elevated triglycerides, a type of fat (lipid), in the blood. Genetic testing may be helpful in determining the underlying cause of a patient’s disease and provide clinical guidance for targeted treatment. ArielDx Lipids may be appropriate for individuals with a personal or familial history of abnormal lipid metabolism and pancreatitis. It is available as an add-on to PancreasDx during the ordering process.
Genes Included in Panel
APOA5, APOC2, FABP4, LPL, PPARG, and a region of interest in APOB exon 29.
Get Started With Your First Order
A New Approach to Complex Disease Care
At Ariel, we believe every patient is unique, therefore every patient’s disease management plan should be too.
That’s why we launched ADVANCE®, a new advanced genetics platform designed specifically for providers to identify and diagnose the underlying biological causes of symptoms and move beyond treating general symptoms.
The ADVANCE Precision Medicine Platform is a clinical decision support platform that simplifies diagnosis and informs more accurate treatment selection at the earliest signs of pancreatic diseases. ADVANCE integrates each individual’s genetics, environment, and family and medical history to provide clinicians more actionable insights into complex diseases, including evidence-based recommendations for management and treatment options.
Our AI powered technology combines deep sequencing genetics with advanced analytics and evidence-based knowledge to provide genetic testing and a report that is actionable and easy to use. Now, care teams can prevent or mitigate the most severe outcomes of complex chronic conditions using a comprehensive understanding of disease drivers and long-term prognoses.
In addition to traditional Mendelian variants, Ariel reports disease modifying and complex genetic variants.
Our reports are tailored to each patient, integrating patient reported outcomes, environmental and medical history into the interpretation of the genetic data.
Our expert system provides you with clinical considerations according to guidelines and continuously updates you and your patients if variants are reclassified.
Our platform uses some of the highest quality next-generation sequencing on the market and our laboratory is CLIA-certified.
How It Works
How Ariel Benefits Providers
Unravel Complex Conditions
Our platform integrates a patient’s symptoms and genetics with complex medical information.
Available Genetic Counseling
Pre- and/or post-test genetic counseling if you need extra help with genetic testing.
Comprehensive Genetic Testing
Analyzes multiple risk factors that are disease causing rather than just assessing single gene risk factors.
Secure Online Test Management
Order and review test results, add medical team and request patient consent using our portal.
ArielDx® Pancreatitis Brochure
How Genetic Testing
Optimizes Clinical Management
There is growing evidence that suggests that most diseases of the pancreas have a genetic predisposition or basis. Genetic testing can help provide advanced insights to help you create a comprehensive and more personalized clinical management plan for your patient.
As an MD, I am frustrated with the lack of effective treatment for pancreatic diseases. As a PhD, I am excited about new breakthroughs in knowledge and possibilities for the future. As a member of the Ariel Team, I am thrilled to see science meet medicine to provide those future solutions – NOW!
David Whitcomb, MD, PhD
Co-Founder and Chairman, Ariel Precision Medicine
Frequently Asked Questions
Frequently asked questions about ArielDx Pancreatitis , ArielDx Lipids, Ariel Precision Medicine, and how you can use genetic information to improve outcomes for your patients.
Identifying the underlying biological causes of symptoms can help direct therapy and guide medical management specific to the patient’s disease process. For example, genetic conditions such as hereditary pancreatitis and cystic fibrosis can both increase the risk of pancreatitis, but involve different treatments and clinical considerations. Early detection of the cause or causes of the disease process may prevent extensive diagnostic evaluations, delayed diagnosis and more severe end-stage disease.
Genetic testing for pancreatitis is recommended for individuals with pancreatitis that meet one or more of the following criteria:
- An unexplained episode of acute pancreatitis in childhood
- Recurrent acute or chronic pancreatitis without a known cause, particularly with early-onset
- A family history of pancreatitis of unknown cause
- A family history of pancreatitis with an established genetic cause
- Additional symptoms consistent with a genetic disorder that includes pancreatitis as a symptom, such as cystic fibrosis or a CFTR-related disorder
Additionally, individuals that meet any of the following criteria may also benefit from genetic testing:
- One or more attacks (or suspected attacks) of acute pancreatitis
- Abdominal pain after eating, chronic diarrhea, abnormal findings on a CT or MRI scan, or an abnormal laboratory test related to the pancreas
- ArielDx® Pancreatitis is a clinician-ordered test. To begin, create an account through the easy-to-use and secure Ariel online provider portal to place the order.
- Once the order is placed, your patient will receive an email from Ariel inviting them to register online, sign test consent forms, access help resources, and complete their health profiles.
- A buccal swab kit will be mailed to your patient’s home. The patient will be provided with instructions to swab the inside of their cheek and return their DNA sample by mail.
- Upon receipt of the DNA sample, completion of genetic testing and subsequent expert review of the findings, your patient’s test results will be released electronically through the secure Ariel portal. Clinicians and staff have a centralized area for managing different patient orders, requesting genetic counseling, and electronic release of results to patients.
The process for adding an ArielDx Lipids order to an existing or completed order is:
- Log into your Ariel account.
- Select the appropriate patient from you dashboard or Patient tab.
- Once you are in the patient’s profile, select “Request Additional Analysis” on the right.
- Check the box next to ArielDx Lipids and select “continue”.
- Authorize the order by checking the box and providing your signature. If you are submitting an order on behalf of an authorizing physician, his or her signature will be required before it can be processed.
The authorizing provider will receive an email notification letting them know to complete this step.
- Results will be released electronically to your Ariel account.
- When a physician orders ArielDx Pancreatitis the patient will receive a ‘Welcome’ email with a link to Ariel’s secure patient portal to register. During registration, they will be asked to provide their insurance information.
- The Ariel team will contact the patient’s insurance to verify eligibility and beneﬁts to assess potential costs for the patient. It is important to note that initial determinations from the patient’s insurance are subject to change, based on the patient’s clinical record and the discretion of the insurer.
- Ariel’s billing team will contact the patient by phone to discuss beneﬁts ﬁndings and the patient’s potential ﬁnancial responsibility (i.e. co-pay, co-insurance, deductible). Ariel works with the patient’s insurance directly through the claims and appeals process. Our team will exhaust all efforts to obtain payment from the patient’s insurance plan to reduce or eliminate patient responsibility for the service. During the billing process, Ariel may ask the ordering provider to supply additional documentation to support the medical necessity of the service for your patient.
Please note: Add-on testing cannot be completed until payment has been resolved.
*The patient-pay price cannot be offered after a claim has been submitted to the insurance.
Checks should be made payable to: Ariel Precision Medicine
Ariel Precision Medicine
Attn: Accounts Receivable
5750 Centre Ave,
Pittsburgh, PA 15206
Ariel is required by law to bill patients for applicable co-pays, co-insurance, and deductibles, as directed by their individual insurance beneﬁt plan. Ariel will partner with the patient to implement the most appropriate payback plan based on the individual’s financial need.
Depending on the patient’s insurance plan, there may be situations where Ariel is considered an out-of-network provider and the payment for our test will be sent to the patient directly. The patient is legally responsible for re-issuing that payment, with a copy of the Explanation of Beneﬁts, to Ariel for processing.
Please tell your patient to expect an email from Ariel. Once you place an order in the secure portal, Ariel will send your patient a ‘Welcome’ email with a link to Ariel’s secure patient portal to register. The patient can then follow the instructions in their email to register in Ariel’s online portal, provide their insurance information and complete the informed consents and their patient profile. Once the requisite forms are compete, Ariel dispatches a DNA testing kit to the patient’s house. This kit also has all the necessary instructions for collecting the sample and shipping it back to Ariel.
Still Have Questions?
If you still have questions, we would love to answer them. Request a quick call with our team and we’ll be in touch.
- Whitcomb DC; North American Pancreatitis Study Group. Pancreatitis: TIGAR-O Version 2 Risk/Etiology Checklist With Topic Reviews, Updates, and Use Primers. Clin Transl Gastroenterol. 2019;10(6):e00027. doi:10.14309/ctg.0000000000000027
- de Pretis N, Amodio A, Frulloni Hypertriglyceridemic pancreatitis: Epidemiology, pathophysiology and clinical management. United European Gastroenterol J. 2018 Jun;6(5):649-655.